Download to Citation Manager

Cell Biology International (2006) 30, 521–524 (Printed in Great Britain)

PDF

Legacy HTML

Citing articles

Human autologous serum obtained using a completely closed bag system as a substitute for foetal calf serum in human mesenchymal stem cell cultures

Noriyoshi Mizuno^a*, Hideki Shiba^a, Yoshitaka Ozeki^a, Yoshihiro Mouri^a, Miyuki Niitani^a, Takafumi Inui^a, Hideaki Hayashi^a, Koji Suzuki^b, Seishin Tanaka^b, Hiroyuki Kawaguchi^a and Hidemi Kurihara^a

^aDepartment of Periodontal Medicine, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8553, Japan
^bJMS Company, Limited, 12-17, Kako-machi, Naka-ku, Hiroshima 730-8652, Japan

Abstract

The major problem in cell therapy is the possibility of viral or bacterial infection and immune reactions. Therefore, it is expected of culture cells which are intended to be re-implanted with autologous serum rather than conventional bovine serum. Cell therapy with human mesenchymal stem cells (hMSC), differentiating to various cells, is thought to be curative. To culture hMSC with human autologous serum (HAS) and re-implant them for cell therapy, we developed a completely closed bag system separating serum, comparing proliferation and multipotency of hMSC cultured in HAS with those in foetal calf serum (FCS). HAS was simply, safely and efficiently obtained with the developed closed bag system. Cell proliferation of hMSC cultured in HAS was greater than that in FCS. hMSC, exposed to the defined induction medium containing HAS as well as FCS, differentiated into osteoblasts and adipocytes. These findings suggest that HAS obtained with the developed closed bag system is advantageous in a point of decrease in risk of virus or bacterial infection and foreign protein contamination and enhancement of proliferation of hMSC.

Key words: Human autologous serum, Human mesenchymal stem cell, Cell therapy, Cell proliferation, Multipotency.

^*Corresponding author. Tel.: +81 82 257 5663; fax: +81 82 257 5664.

Received 17 June 2005/9 November 2005; accepted 30 January 2006